Chemify Chemputation Platform

Chemify is a chemistry company based in Glasgow, UK, where its Advanced Research Centre and the Maryhill Chemifarm are located. It aims to digitize molecule creation so that designed molecules can be made as physical compounds on demand.

Its Chemputation platform combines quantum-based molecule design, the ASSEMBLER route-optimization software, the chi-DL hardware-agnostic chemical programming language, and robotics for synthesis, workup, purification and analysis. A closed Design-Make-Test-Analyze loop feeds data back into machine learning models. Partners can engage through the Partner With Us channel.

• Quantum Chemputation: combines quantum mechanics, inverse design and Chemputation for synthetically tractable designs.
• ASSEMBLER: software that finds efficient synthetic routes from a database of automated reaction classes.
• chi-DL language: hardware-agnostic chemical programming language for synthesis.
• Advanced robotics: executes reaction optimization, synthesis, workup, purification and analysis.
• Data and machine learning: real-time monitoring of reaction variables to improve predictions.

Outsourced synthesis of designed compounds for drug discovery teams. Route optimization for specialty chemical development. Joint research on small-molecule leads for neglected diseases with local institutes.

Links computational design to physical synthesis in one loop. Every design is intended to be synthetically tractable. Real-time monitoring of reagents, temperature, pressure and yield supports error prevention. A hardware-agnostic chemical programming language allows reactions to be reproduced across robotic setups.

Pharma and chemical groups are looking for ways to make molecule creation faster and more reproducible through automation and AI. Vietnamese pharmaceutical, specialty chemical and university groups are more likely to join through research collaborations and compound-synthesis partnerships than through direct purchase.

Chemify, Glasgow, UK. News page lists a Series B of more than USD 50 million (October 2025), the opening of a Chemputation facility (June 2025), a strategic investment from Zeon (February 2026), a collaboration with Sanacor (February 2026) and GBP 22 million in grants (September 2026).